Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (2,030)	$ (1,906)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	801	647
Depreciation and amortization	476	545
Gain on sale of equipment	(625)
Loss on disposition of Tantaline		162
Provision for excess and obsolete inventory	1,253	197
Impairment charge		111
Changes in assets and liabilities, net of effects of disposition of Tantaline and sale of equipment:
Accounts receivable	(3,218)	1,163
Contract assets	256	(725)
Inventories	633	(1,953)
Employee retention credit receivable		1,529
Other current assets	48	(46)
Other noncurrent assets	8
Accounts payable	140	113
Accrued expenses	138	(729)
Contract liabilities	(1,620)	816
Net cash used in operating activities	(3,740)	(76)
Cash flows from investing activities:
Purchases of property and equipment	(219)	(308)
Deposits from purchaser of MesoScribe assets		597
Net cash used in connection with disposition of Tantaline		(312)
Net cash used in investing activities	(219)	(23)
Cash flows from financing activities
Payments of long-term debt	(61)	(57)
Proceeds from exercise of stock options		76
Net cash (used in) provided by financing activities	(61)	19
Net decrease in cash and cash equivalents	(4,020)	(80)
Cash and cash equivalents at beginning of period	14,025	14,365
Cash and cash equivalents at end of period	10,005	14,285
Supplemental disclosure of cash flow information:
Income taxes paid	2	11
Interest paid	$ 14	$ 18